Table 3 Basic characteristics of included study
Author | Year | Clinical trial number | phase | Number of experimental groups | Number of control group | Indication | Countris/Area | Age, median | Gender, male (%) |
|---|---|---|---|---|---|---|---|---|---|
David A. Reardon | 2020 | NCT02017717 | 3 | 185 | 184 | Glioblastoma | 12 countries | 55 (22–76) | 119 (64.3) |
Chiara Cremolini | 2018 | NCT02295930 | 2 | 69 | 74 | Colorectal cancer | IT | 59 (53‐67) | 42 (74) |
Ingrid U Scott | 2017 | NCT01969708 | 3 | 182 | 180 | Macular edema | US | 69 (15verage) | 107 (58.8) |
Cesare Gridelli | 2018 | NCT01351415 | 3 | 243 | 232 | NSCLC | several countries | 63 (26–84) | 155 (63.3) |
Hiroaki Akamatsu | 2020 | UMIN000023761 | 2 | 40 | 41 | NSCLC | unknown | 68 (41–82) | 31 (47) |
Marla Lipsyc-Sharf | 2022 | NCT02292758 | 2 | 19 | 17 | Colorectal cancer | US | 55 (48–65) | 20 (55.6) |
Sermsiri Sangroongruangsri | 2018 | TCTR20141002001 | 3 | 5975 | 379 | Retinal disease | THA | 58 (average) | 3000 (47.2) |
Matthew H Kulke | 2022 | NCT01229943 | 2 | 75 | 75 | pNETS | unknown | 56 (21–86) | 84 (56) |